Physician profile
Charles J Breen
NPI 1114944113
$1,412.42
in general payments reported to CMS, 2019-2025
31 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.30 · 2020: $193 · 2021: $326 · 2022: $224 · 2023: $160 · 2024: $179 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.99 | 2019-2023 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $128.80 | 2021 | |
| Phathom Pharmaceuticals, INC. | $66.61 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $62.13 | 2021-2024 | Jardiance, Mounjaro |
| Mylan Specialty L.P. | $57.34 | 2020-2024 | Yupelri |
| Abbvie INC. | $55.78 | 2021-2024 | |
| Acadia Pharmaceuticals INC | $48.74 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.08 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $39.99 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $37.54 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.70 | 2022-2024 | Eliquis |
| Astellas Pharma US INC | $32.91 | 2020 | |
| Merck Sharp & Dohme LLC | $31.91 | 2021-2025 | Vaxelis, Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals Lp | $25.96 | 2020-2023 | Farxiga |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.83 | 2020 | |
| Lundbeck LLC | $20.42 | 2024 | Rexulti |
| Abbott Laboratories | $17.92 | 2021 | |
| Genzyme Corporation | $17.73 | 2023 | |
| Pfizer INC. | $17.14 | 2023 | |
| Nestle Healthcare Nutrition INC. | $16.72 | 2023 | |
| Viatris Specialty LLC | $14.30 | 2025 | Yupelri |
| Alkermes, INC. | $14.17 | 2023 | Lybalvi |
| Exact Sciences Corporation | $14.04 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2021 | |
| Sanofi Pasteur INC. | $13.22 | 2023 | |
| Esperion Therapeutics, INC. | $12.35 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.73 | 2022 | |
| Biogen, INC. | $11.14 | 2021 | |
| Eisai INC. | $11.08 | 2021 | |
| Dynavax Technologies Corporation | $6.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.